to test the hypothesis that selegiline ( l-deprenyl ) , a selective inhibitor of b-type monoamine oxidase , can halt the natural progression of parkinson 's disease , its use in 22 naive patients ( mean age , 58 years ; mean parkinson 's disease duration , 2.3 years ) in the early stages ( 1 to 2 ) of the disease was studied .
C0036579
l-deprenyl
C0030567
parkinson 's